BAT-6026 is under clinical development by Bio-Thera Solutions and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BAT-6026’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BAT-6026 is under development for the treatment of advanced malignant solid tumor. The drug candidate is a monoclonal antibody with afucosylated modification that targets OX40. BAT6026 discovered using Bio-Thera’s proprietary IDEAL (Intelligent Design and Engineered Antibody Libraries) platform.
Bio-Thera Solutions overview
Bio-Thera Solutions (Bio-Thera) is a clinical-stage biopharmaceutical company that carries out the research and development, production of innovative drugs and biosimilars. The company’s pipeline products include humanized monoclonal antibodies and peptide drugs such as BAT8001, BAT8003, BAT1306, BAT2094, and BAT4306F. It also offers BAT1406, an adalimumab biosimilar; BAT1706, a bevacizumab biosimilar; BAT1806, a tocilizumab biosimilar; and BAT2506. Bio-Thera develops its products and therapies for the treatment of indications such as cancer, autoimmune diseases, cardiovascular diseases, arthritis, Crohn’s disease, psoriasis, polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA). The company operates a research and development center, manufacturing, and clinical facility in China. Bio-Thera is headquartered in Guangzhou, Guangdong, China.
For a complete picture of BAT-6026’s drug-specific PTSR and LoA scores, buy the report here.